|
Resources
References
-
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P and Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood, 99: 754-758.
-
Weng W-K and Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21(21): 3940-3947.
-
Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, and Thibault G. 2004. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on concentration-effect relationship. Cancer Research, 64:4664-4669.
Links
National Cancer Institute
www.cancer.gov
American Cancer Society
www.cancer.org
Rituxan® Product Information
www.rituxan.com
Rituximab is sold as Rituxan® in the United States. All trademarks are the property of their respective owners.
1-877-2-PGXHEALTH (877-274-9432)
|
